Primidon je organsko jedinjenje, koje sadrži 12 atoma ugljenika i ima molekulsku masu od 218,252 Da.[1][2][3][4][5][6][7]

Primidon
Klinički podaci
Prodajno imeApo-Primidone, Cyral, Desoxyphenobarbitone, Hexadiona
Drugs.comMonografija
Način primeneOralno
Farmakokinetički podaci
Poluvreme eliminacije3-23 h
Identifikatori
CAS broj125-33-7 ДаY
ATC kodD08AC04 (WHO), N03AA03
PubChemCID 4909
DrugBankDB00794 ДаY
ChemSpider4740 ДаY
KEGGC07371 ДаY
ChEMBLCHEMBL856 ДаY
Hemijski podaci
FormulaC12H14N2O2
Molarna masa218,252
  • CCC1(C(=O)NCNC1=O)C1=CC=CC=C1
  • InChI=1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16) ДаY
  • Key:DQMZLTXERSFNPB-UHFFFAOYSA-N ДаY
Fizički podaci
Tačka topljenja2.815 °C (5.099 °F)
Osobina Vrednost
Broj akceptora vodonika 2
Broj donora vodonika 2
Broj rotacionih veza 2
Particioni koeficijent[8] (ALogP) 0,9
Rastvorljivost[9] (logS, log(mol/L)) -2,3
Polarna površina[10] (PSA, Å2) 58,2

Reference

уреди
  1. ^ Murphy K, Delanty N: Primary Generalized Epilepsies. Curr Treat Options Neurol. 2000 Nov;2(6):527-542. PMID 11096777
  2. ^ Kagitani-Shimono K, Imai K, Okamoto N, Ono J, Okada S: Unverricht-Lundborg disease with cystatin B gene abnormalities. Pediatr Neurol. 2002 Jan;26(1):55-60. PMID 11814737
  3. ^ Brown GM, Stone GH, Rathbone MP: Primidone and rapid cycling affective disorders. Lancet. 1993 Oct 9;342(8876):925. PMID 8105181
  4. ^ Schaffer LC, Schaffer CB, Caretto J: The use of primidone in the treatment of refractory bipolar disorder. Ann Clin Psychiatry. 1999 Jun;11(2):61-6. PMID 10440522
  5. ^ Young MC, Hughes IA: Loss of therapeutic control in congenital adrenal hyperplasia due to interaction between dexamethasone and primidone. Acta Paediatr Scand. 1991 Jan;80(1):120-4. PMID 2028784
  6. ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126. 
  7. ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug _targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. 
  8. ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 
  9. ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t. 
  10. ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e. 

Literatura

уреди

Spoljašnje veze

уреди


 Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).
  NODES
Done 5
eth 3